Abstract
Objective This study examined the association between the prevalence of cardiometabolic disease and fat-enlarged lymph nodes (LNs), identified on digital screening mammography.
Methods A cross-sectional study on 834 women presenting for full-field digital screening mammography was conducted. The status of fat-enlarged LNs was assessed based on the size and morphology of axillary LNs from the mammograms. The prevalence of cardiometabolic disease, including type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, high blood glucose, cardiovascular disease, stroke, and non-alcoholic fatty liver disease, were retrieved from the electronic medical records.
Results Fat-enlarged axillary LNs were associated with a high prevalence of T2DM among all women (adjusted odds ratio: 3.92, 95% CI: [2.40, 6.60], p-value < 0.001), and in subgroups of women with and without obesity. Utilizing the status of fatty LNs improved the classification of T2DM status in addition to age and BMI (1.4% improvement in the area under the receiver operating characteristic curve).
Conclusion Fat-enlarge axillary LNs visualized on screening mammograms were associated with the prevalence of T2DM. If further validated with larger datasets from external institutions, fat-enlarged axillary LNs may become a novel imaging biomarker in clinical practice to improve the risk assessment of T2DM for women with screening mammography.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported in part by grants from the US National Institute of Health (R01CA249758, R01LM012837, P20GM104416).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is approved by Dartmouth-Hitchcock Medical Center Institutional Review Board with a waiver of informed consent and is compliant with Health Insurance Portability and Accountability Act (HIPPA).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This research was supported in part by grants from the US National Institute of Health (R01CA249758, R01LM012837, P20GM104416).
Conflicts of Interest: The authors have no conflicts of interest to disclose.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos